Development of engineered IL-36γ-hypersecreting Lactococcus lactis to improve the intestinal environment
World Journal of Microbiology and Biotechnology · 2024
DOI: 10.1007/s11274-024-04157-x ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Microbiology and Biotechnology, 2024. Verfasst von Masahiro Yoda und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomolecular Innovation, Institute for Biomedical Sciences, Shinshu University, Nagano, 399-4598, Japan. Hauptthemen laut MEDLINE: Lactococcus lactis, Interleukin-1. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shinshu University.
Abstract (Originalsprache)
Interleukin (IL) 36 is a member of the IL-1-like proinflammatory cytokine family that has a protective role in mucosal immunity. We hypothesized that mucosal delivery of IL-36γ to the intestine would be a very effective way to prevent intestinal diseases. Here, we genetically engineered a lactic acid bacterium, Lactococcus lactis , to produce recombinant mouse IL-36γ (rmIL-36γ). Western blotting and enzyme-linked immunosorbent assay results showed that the engineered strain (NZ-IL36γ) produced and hypersecreted the designed rmIL-36γ in the presence of nisin, which induces the expression of the recombinant gene. We administered NZ-IL36γ to mice via oral gavage, and collected the ruminal contents and rectal tissues. Colony PCR using primers specific for NZ-IL36γ, and enzyme-linked immunosorbent assay to measure the rmIL-36γ concentrations of the ruminal contents showed that NZ-IL36γ colonized the mouse intestines and secreted rmIL-36γ. A microbiota analysis revealed increased abundances of bacteria of the genera Acetatifactor , Eubacterium , Monoglobus , and Roseburia in the mouse intestines. Real-time quantitative PCR of the whole colon showed increased Muc2 expression. An in vitro assay using murine colorectal epithelial cells and human colonic cells showed that purified rmIL-36γ promoted Muc2 gene expression. Taken together, these data suggest that NZ-IL36γ may be an effective and attractive tool for delivering rmIL-36γ to improve the intestinal environment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomolecular Innovation, Institute for Biomedical Sciences, Shinshu University, Nagano, 399-4598, Japan.
- Food and Feed Immunology Group, Laboratory of Animal Food Function, Graduate School of Agricultural Science, Tohoku University, Sendai, Miyagi, 980-8572, Japan.
- Department of Medical Research on Prebiotics and Probiotics, Fujita Health University, Toyoake, Aichi, 470-1101, Japan.
- Department of Biomolecular Innovation, Institute for Biomedical Sciences, Shinshu University, Nagano, 399-4598, Japan. shimot@shinshu-u.ac.jp.
- Institute for Aqua Regeneration, Shinshu University, Nagano, 399-4598, Japan. shimot@shinshu-u.ac.jp.
- Department of Pharmacy, Medical Faculty, Universitas Brawijaya, Malang, 65145, Indonesia. shimot@shinshu-u.ac.jp.
Förderung
- Shinshu University
Zitieren
APA
Yoda, M., Takase, S., Suzuki, K., Murakami, A., Namai, F., Sato, T., Fujii, T., Tochio, T., & Shimosato, T. (2024). Development of engineered IL-36γ-hypersecreting Lactococcus lactis to improve the intestinal environment. World Journal of Microbiology and Biotechnology. https://doi.org/10.1007/s11274-024-04157-x
Vancouver
Yoda M, Takase S, Suzuki K, Murakami A, Namai F, Sato T, et al. Development of engineered IL-36γ-hypersecreting Lactococcus lactis to improve the intestinal environment. World Journal of Microbiology and Biotechnology. 2024. doi:10.1007/s11274-024-04157-x
BibTeX
@article{Yoda2024,
author = {Yoda, Masahiro and Takase, Shogo and Suzuki, Kaho and Murakami, Aito and Namai, Fu and Sato, Takashi and Fujii, Tadashi and Tochio, Takumi and Shimosato, Takeshi},
title = {Development of engineered IL-36γ-hypersecreting Lactococcus lactis to improve the intestinal environment},
journal = {World Journal of Microbiology and Biotechnology},
year = {2024},
doi = {10.1007/s11274-024-04157-x}
}
EUVIMED